EMA Authorised: Sirturo (bedaquiline fumarate) — Janssen-Cilag International N.V.

View source ↗

Summary

EMA authorises Sirturo (bedaquiline fumarate) for multidrug-resistant tuberculosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multidrug-resistant Tuberculosis
• Tuberculosis

Drugs mentioned

• SIRTURO (bedaquiline fumarate)

Snippet

Status: Authorised. Therapeutic area: Tuberculosis, Multidrug-Resistant. MAH: Janssen-Cilag International N.V.. Decision date: 02/06/2026